Hypolipidemic effectiveness and safety of generic lovastatin
Aim. To study hypolipidemic effectiveness and safety of generic lovastatin (Cardiostatin®). Material and methods. This open, cooperative study included 90 patients with coronary heart disease (CHD) and hypercholesterolemia (<10 mmol/l). All patients received Cardiostatin® in the dose of 20 mg...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2006-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1404 |
| _version_ | 1797882720837173248 |
|---|---|
| author | D. M. Aronov V. V. Kukharchuk V. G. Kukes M. G. Bubnova |
| author_facet | D. M. Aronov V. V. Kukharchuk V. G. Kukes M. G. Bubnova |
| author_sort | D. M. Aronov |
| collection | DOAJ |
| description | Aim. To study hypolipidemic effectiveness and safety of generic lovastatin (Cardiostatin®). Material and methods. This open, cooperative study included 90 patients with coronary heart disease (CHD) and hypercholesterolemia (<10 mmol/l). All patients received Cardiostatin® in the dose of 20 mg/d, increased up to 40-80 mg/d, if needed. Dynamics of total cholesterol (TCH), low-density lipoprotein CH (LDL-CH), high-density lipoprotein CH (HDL-CH), triglycerides, hepatic enzymes, and C-reactive protein (CRP) levels was studied. Results. Cardiostatin® improved lipid profile to the same extent as original lovastatin. Target TCH level (<2,5 mmol/l) was achieved in 68,8% of the patients. In participants with initially increased CRP level, it had significantly reduced. Conclusion. Cardiostatin® demonstrated good hypolipidemic effects, at the same time reducing increased CRP level. Cardiostatin can be recommended for dyslipidemia and atherosclerotic pathology treatment. |
| first_indexed | 2024-04-10T03:40:20Z |
| format | Article |
| id | doaj.art-282daea74926434c9636989814ede922 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:40:20Z |
| publishDate | 2006-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-282daea74926434c9636989814ede9222023-03-13T07:23:13Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252006-12-015646521114Hypolipidemic effectiveness and safety of generic lovastatinD. M. Aronov0V. V. Kukharchuk1V. G. Kukes2M. G. Bubnova3Государственный научно-исследовательский центр профилактической медицины РосздраваНИИ клинической кардиологии им. А.Л. Мясникова РК НПК РосздраваМосковская медицинская академия им. И.М.Сеченова Росздрава. МоскваГосударственный научно-исследовательский центр профилактической медицины РосздраваAim. To study hypolipidemic effectiveness and safety of generic lovastatin (Cardiostatin®). Material and methods. This open, cooperative study included 90 patients with coronary heart disease (CHD) and hypercholesterolemia (<10 mmol/l). All patients received Cardiostatin® in the dose of 20 mg/d, increased up to 40-80 mg/d, if needed. Dynamics of total cholesterol (TCH), low-density lipoprotein CH (LDL-CH), high-density lipoprotein CH (HDL-CH), triglycerides, hepatic enzymes, and C-reactive protein (CRP) levels was studied. Results. Cardiostatin® improved lipid profile to the same extent as original lovastatin. Target TCH level (<2,5 mmol/l) was achieved in 68,8% of the patients. In participants with initially increased CRP level, it had significantly reduced. Conclusion. Cardiostatin® demonstrated good hypolipidemic effects, at the same time reducing increased CRP level. Cardiostatin can be recommended for dyslipidemia and atherosclerotic pathology treatment.https://cardiovascular.elpub.ru/jour/article/view/1404атеросклерозстатиныцелевые уровни холестеринавторичная профилактика |
| spellingShingle | D. M. Aronov V. V. Kukharchuk V. G. Kukes M. G. Bubnova Hypolipidemic effectiveness and safety of generic lovastatin Кардиоваскулярная терапия и профилактика атеросклероз статины целевые уровни холестерина вторичная профилактика |
| title | Hypolipidemic effectiveness and safety of generic lovastatin |
| title_full | Hypolipidemic effectiveness and safety of generic lovastatin |
| title_fullStr | Hypolipidemic effectiveness and safety of generic lovastatin |
| title_full_unstemmed | Hypolipidemic effectiveness and safety of generic lovastatin |
| title_short | Hypolipidemic effectiveness and safety of generic lovastatin |
| title_sort | hypolipidemic effectiveness and safety of generic lovastatin |
| topic | атеросклероз статины целевые уровни холестерина вторичная профилактика |
| url | https://cardiovascular.elpub.ru/jour/article/view/1404 |
| work_keys_str_mv | AT dmaronov hypolipidemiceffectivenessandsafetyofgenericlovastatin AT vvkukharchuk hypolipidemiceffectivenessandsafetyofgenericlovastatin AT vgkukes hypolipidemiceffectivenessandsafetyofgenericlovastatin AT mgbubnova hypolipidemiceffectivenessandsafetyofgenericlovastatin |